Clinical trials: Hook Worm
Trichuriasis, Ascariasis
Efficacy and Safety of MOX/ALB vs. IVM/ALB Co-administration
The aim of this randomized controlled trial is to provide evidence on the efficacy and safety of co-administered moxidectin and albendazole compared to co-administered ivermectin and albendazole, and to assess the efficacy of the…
- Conditions
- Trichuriasis, Ascariasis, Hookworm Infections, Helminthes; Infestation, Intestinal
- Trial name
- NCT04700423
- Testing
- moxidectin (8 mg) / albendazole (400 mg), ivermectin (200 µg/kg) / albendazole (400 mg), ALBENDAZOLE 400 Mg ORAL TABLET [ZENTEL]
- Where
- Tanzania
- Volunteers
- 536 people
- Sponsor
- Jennifer Keiser
Trichuriasis, Ascariasis
Efficacy, Safety and Acceptability of Ivermectin ODT in PSAC
This study is a single-blind randomized controlled dose-ranging trial aiming at providing evidence on the on the optimal dose of co-administered ivermectin and albendazole in terms of efficacy, safety and acceptability in…
- Conditions
- Trichuriasis, Ascariasis, Hookworm Infections
- Trial name
- Iverped (NCT06184399)
- Testing
- Ivermectin 1.5 mg ODT, Ivermectin 3 mg Oral Tablet, Albendazole 400 mg Oral Tablet
- Where
- Tanzania
- Volunteers
- 260 people
- Sponsor
- Jennifer Keiser
Hookworm Infection, Hookworm Disease
Study of Na-APR-1 (M74)/Alhydrogel® Co-administered With Na-GST-1/Alhydrogel in Brazilian Adults
Na-GST-1 and Na-APR-1 are proteins expressed during the adult stage of the Necator americanus hookworm life cycle that are thought to play a role in the parasite's degradation of host hemoglobin for use as an energy source.
- Trial name
- NCT02476773
- Testing
- Na-GST-1/Alhydrogel plus GLA-AF, Na-APR-1 (M74)/Alhydrogel, Na-APR-1 (M74)/Alhydrogel plus GLA-AF
- Where
- Brazil
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Baylor College of Medicine
Hookworm Infection, Hookworm Disease
Safety and Immunogenicity of a Human Hookworm Candidate Vaccine With or Without Additional Adjuvant in Brazilian Adults
This two part study will evaluate the safety and immunogenicity of two formulations of Na-GST-1, first in hookworm-naïve individuals using an open-label design, and then in adults living in an area of endemic hookworm infection…
- Trial name
- NCT01261130
- Testing
- 10 μg Na-GST-1/Alhydrogel, 30 μg Na-GST-1/Alhydrogel, 100 μg Na-GST-1/Alhydrogel
- Where
- 2 sites in Brazil
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Baylor College of Medicine